Add BrightSurf on Google Email

From inhibition to destruction – kinase drugs found to trigger protein degradation

A new study reveals that kinase inhibitors can accelerate the degradation of targeted proteins, which is not a rare quirk but a common mechanism. This discovery could help design better drugs that remove kinases altogether or explain unexpected effects of existing therapies.

Researchers uncover potential mechanism driving treatment resistance in common breast cancer

A study at the Garvan Institute of Medical Research found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment. The JNK pathway acts as a cellular alarm system, and its disruption leads to treatment resistance.

SourceGarvan Institute of Medical Research·JournalJournal of Experimental & Clinical Cancer Research·TypeExperimental study·DateAug 18, 2025

Shedding light on why immunotherapy sometimes fails

Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.

SourceChiba University·JournalInternational Journal of Pharmaceutics·TypeExperimental study·DateJul 24, 2025

Investigational anti-cancer DNA therapy eases chronic osteoarthritis pain in dogs—pointing to a new non-opioid path for humans

A study published in Frontiers in Veterinary Science found that Elenagen significantly reduced chronic osteoarthritis pain scores in dogs, achieving a 90% success rate. The therapy works by reprogramming aged or dysfunctional mesenchymal stem cells, which then produce anti-inflammatory signals and restore their regenerative capacity.

SourceCureLab Oncology Inc.·JournalFrontiers in Veterinary Science·TypeExperimental study·DateJul 22, 2025

Good prognosis for men with prostate cancer treated according to guidelines

A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.

SourceUppsala University·JournalJournal of the National Comprehensive Cancer Network·TypeObservational study·DateJul 14, 2025

CPRIT awards UT Health San Antonio $3.4 million to target drug-resistant cancers, raise HPV vaccination rates

The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.

Patients are opting in for 10 years of breast cancer treatment

A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.

SourceMichigan Medicine - University of Michigan·JournalJNCI Journal of the National Cancer Institute·TypeSurvey·DateJun 9, 2025

Cancer treatments should be licensed for all ages, oncologists say

Recent advances in tissue-agnostic cancer drugs have resulted in highly effective treatments, but few are approved for children. Oncologists argue that these drugs should be licensed for all ages due to their effectiveness and fewer side effects. The researchers suggest that age-agnostic approvals could be made through analyzing electr...

SourceCell Press·JournalTrends in Cancer·TypeCommentary/editorial·DateJun 5, 2025

New drug combination increases overall survival in patients with PIK3CA-mutated advanced breast cancer

A new drug combination has shown significant improvements in overall survival for patients with advanced breast cancer who have the PIK3CA gene mutation. The treatment, which includes inavolisib, palbociclib, and fulvestrant, was found to extend median overall survival by 7 months compared to the placebo group.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 2, 2025

New study advances cancer precision therapies by identifying patients who benefit from Bexmarilimab treatment

A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.

SourceUniversity of Turku·JournalJournal for ImmunoTherapy of Cancer·DateMay 20, 2025

Breakthrough in anal cancer treatment

A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

A new voluntary program, the Medicare Prescription Payment Plan (MPPP), could greatly reduce out-of-pocket costs for Medicare patients taking expensive oral cancer drugs. By spreading annual costs across 12 monthly payments, patients can avoid large upfront payments and make treatment more affordable.

SourceUniversity of Pennsylvania School of Medicine·JournalJCO Oncology Practice·DateApr 25, 2025

UT Health San Antonio-led discovery means IV medication could be taken orally for range of cancer, Alzheimer’s treatments

A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.

SourceUniversity of Texas Health Science Center at San Antonio·JournalCell·TypeExperimental study·DateApr 21, 2025

Scientists hack cell entry to supercharge cancer drugs

Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.

SourceDuke University·JournalCell·TypeExperimental study·DateApr 17, 2025